Alkermes plc
Alkermes plc (ALKS) is a biopharmaceutical company focused on developing medicines for people living with serious neuropsychiatric, neurologic and addiction disorders. The company combines proprietary formulation and delivery technologies with a pipeline that includes marketed products and earlier-stage candidates. Its revenues come from product sales, royalties and partner collaborations, while research and development is a major cost driver. Investors should be aware that Alkermes is R&D‑intensive and sensitive to clinical trial results, regulatory approvals and reimbursement decisions — outcomes that can materially affect valuation. With a market capitalisation around $5.2bn, Alkermes occupies a mid-cap position in the biotechnology sector, offering exposure to neuroscience therapeutics but also carrying typical sector volatility. This summary is educational only and not personal financial advice; prospective investors should review the company’s latest filings and consider their own risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Alkermes' stock with a target price of $43.88, indicating good growth potential.
Financial Health
Alkermes is performing well with strong revenue, profits, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ALKS
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical and regulatory milestones can move the share price; watch study readouts and approvals, though outcomes are uncertain.
R&D Intensity
High R&D spending supports innovation but increases cash-burn risk; funding and trial success are important to monitor.
Commercial & Partnerships
Revenue is a mix of product sales, royalties and collaborations; commercial uptake and payer decisions influence growth, and competition remains.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
